U.S. biotech startup Loyal plans to launch a lifespan-extending drug for dogs in early 2024, potentially offering insights into human longevity. The San Francisco-based company has secured $125 million in funding for LOY-002, a beef-flavored daily pill designed to extend canine lifespans by at least one year. The drug works by targeting age-related metabolic changes and insulin regulation, according to Loyal CEO Celine Halioua.
Simultaneously, the Dog Aging Project is studying rapamycin, an immunosuppressant drug, which preliminary research suggests could add three years to dogs’ lives. Researchers believe these canine studies could accelerate human longevity research, though experts note the lack of standardized aging biomarkers remains a significant hurdle for human trials.